Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 2/20 | 0.34 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.32 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30226522 | 1.00 | CYP17A1 (0.35) | CYP17A1CYP1A2MAPTATRATRIP | |
| SCHEMBL27200482 | 0.84 | CYP17A1 (0.35) | CYP17A1CYP1A2MAPTATRATRIP | |
| SCHEMBL25324687 | 0.84 | DGAT1 (0.37) | CYP17A1CYP1A2MAPTATRATRIP | |
| SCHEMBL30413120 | 0.84 | DGAT1 (0.37) | CYP17A1CYP1A2MAPTATRATRIP | |
| SCHEMBL29514122 | 0.82 | MAPT (0.36) | CYP17A1CYP1A2MAPTATRATRIP | |
| SCHEMBL26720199 | 0.82 | MAPT (0.36) | CYP17A1CYP1A2MAPTATRATRIP | |
| SCHEMBL1441946 | 0.80 | LMNA (0.37) | KMT2ALMNAMEN1HTT | |
| SCHEMBL30365647 | 0.79 | MAPT (0.31) | CYP17A1CYP1A2MAPTATRATRIP | |
| SCHEMBL27200473 | 0.79 | MAPT (0.31) | CYP17A1CYP1A2MAPTATRATRIP | |
| SCHEMBL29662049 | 0.79 | MAPT (0.35) | MAPTATRATRIPDGAT1F2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011299-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-01-09 | — | — | US | disclosed |
| CN-118201915-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| EP-4182323-B1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-04-24 | — | — | EP | disclosed |
| EP-3444251-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-116075307-A | Pyridooxazine amino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-05 | — | — | CN | disclosed |
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3444251-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Biogen MA Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3080122-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20160318935-A1 | BIARYL BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2016-11-03 | — | — | US | disclosed |
| EP-3080122-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Biogen MA Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089327-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN IDEC MA INC. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318935-A1 | BIARYL BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, LYN | CYP17A1 2165/4885CYP1A2 2609/4885MAPT 4569/4885 |
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | ABL1, BTK, LYN | CYP17A1 2165/4885CYP1A2 2609/4885MAPT 4569/4885 |
| US-20250011299-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | CYP17A1 2846/4885CYP1A2 3069/4885MAPT 2942/4885 |
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | TGFBR1, ACVR1, ALK | CYP17A1 2244/4885CYP1A2 2154/4885MAPT 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.